A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
Clinical trial NCT03330418 · TERMINATED
Trial details
- NCT number
- NCT03330418
- Sponsor
- RemeGen Co., Ltd.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-29
- Primary completion
- 2026-04-03
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.